S

Sanofi

Global pharma company; vaccines and R&D

Filter Validation Execution Lead

Full-TimePosted on 10/15/2026Deadline 10/30/26
$85.5k - $123.5k
Junior
Bachelor's
Swiftwater, PA, USA
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Demonstrated experience managing execution deliverables to achieve strategic objectives.
  • Contributing to collaboration and harmonization initiatives in support of a vision for future production processes and technologies.
  • Ability to work with a high level of autonomy with limited guidance.
  • Knowledge of regulatory expectations around filter design, qualification, and testing, including FDA, EMA, and PDA Technical Reports.
  • At least 2 years of hands-on experience qualifying and testing filters used in vaccine manufacturing.
  • Strong communication skills to discuss technical topics effectively through oral and written communication.
  • Bachelor’s degree in basic sciences, mathematics, engineering, or pharmacy, with at least 2 years of work experience in the Filter Validation field.
  • Educational and professional experience commensurate with the position.
  • Ability to work normal business hours, 8 a.m. to 5 p.m. Monday through Friday, with flexibility for occasional work outside those hours.
Responsibilities
  • Design and execute development and validation studies for sterilizing-grade filters, virus filtration filters, bioburden reduction filters, and vent filters.
  • Manage study execution aligned with the project schedule and communicate with external labs, the project team, and MSAT Management.
  • Partner with MSAT product experts to assess new filtration needs and support screening studies to define and optimize filter selection.
  • Draft, review, and approve filter validation protocols, reports, Validation Project Plans, technical assessments, and deviations.
  • Drive Corrective and Preventive Actions and Change Controls related to filter development and validation.
  • Coach and mentor junior personnel and contractors on technical knowledge regarding filter validation principles and practices.
  • Support the Subject Matter Expert in optimizing the filter validation program and ensuring compliance with changes to filter validation guidelines.
  • Support internal and external audits and regulatory inspections related to filter validation.
  • Participate in the filtration validation expertise network within Sanofi and externally.
  • Lead or participate in filter validation investigations and troubleshooting activities.
  • Build and maintain relationships with partners, cross-functional experts, and customers to achieve technical objectives.
  • Propose continuous improvements that deliver efficiency gains.
  • Communicate successes, constraints, conflicts, solutions, and actions for resolution.
  • Resolve conflicts and remove execution roadblocks within the role’s sphere of influence, escalating to functional management when appropriate.
Desired Qualifications
  • At least 2 years of experience in protocol writing, data pack assembly, and report writing for filter validation.
  • Experience in cleaning, shipping, and Extractables and Leachables validation.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...